I. INTRODUCTION
As implementation of the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC) accelerates and states seek to address risk factors for non-communicable disease more broadly, tension has increased between the law of the World Trade Organization (WTO) and public health. For example, Indonesia recently brought a successful claim against a U.S. law that prohibits cigarettes with a characterizing flavor other than menthol or tobacco.
1 Indonesia succeeded in arguing that the regulation discriminates against clove-flavored cigarettes of Indonesian origin in favor of menthol-flavored cigarettes of U.S. origin.
TOBACCO CONTROL AND BEYOND 267 Document which lays down product characteristics or their related processes and production methods, including the applicable administrative provisions, with which compliance is mandatory. It may also include or deal exclusively with terminology, symbols, packaging, marking or labelling requirements as they apply to a product, process or production method. 12 The heart of the definition is such that the document in question must lay down product characteristics in order to be a technical regulation. These characteristics may be in a negative form, such as a prohibition, or in a positive form, such as a compulsion. 13 In the tobacco control context, there is a limited range of measures that constitute technical regulations. The most obvious examples are packaging and labeling requirements and requirements concerning the constituents of tobacco products. The TBT Agreement does not, however, ordinarily apply to taxes or to restrictions on marketing that are commonly used to reduce tobacco consumption but that do not lay down product characteristics. 14 In the contexts of alcohol and diet, the question of scope is more complex. Article 1.5 of the TBT Agreement provides that the agreement does not apply to measures falling within the scope of the Agreement on the Application of Sanitary and Phytosanitary Measures (the "SPS Agreement"). 15 The SPS Agreement applies to a broad range of measures, including any measure "to protect human or animal life or health within the territory of the Member from risks arising from additives, contaminants, toxins or disease-causing organisms in foods, beverages or feedstuffs." 16 The types of measures covered are described in the following way:
Sanitary or phytosanitary measures include all relevant laws, decrees, regulations, requirements and procedures including, inter alia, end product criteria; processes and production methods; testing, inspection, certification and approval procedures; quarantine treatments including relevant requirements associated with the transport of animals or plants, or with the materials necessary for their survival during transport; provisions on relevant statistical methods, sampling procedures and methods of risk assessment; and packaging and labelling requirements directly related to food safety. 17 Accordingly, most product regulations in the food context, and food labeling measures, will fall within the scope of the SPS Agreement rather than the TBT Agreement. 18 In the alcohol context, some measures fall outside the scope of the TBT Agreement and others fall within the scope of the SPS Agreement. Regulations governing the constituents of alcoholic beverages in order to reduce toxicity would A number of other alcohol control regulations would appear to lay down product characteristics and thereby fall within the scope of the TBT Agreement. Labeling measures are one example. Other examples include measures that prohibit the sale of "alcopops" (pre-mixed drinks targeted at young people) and regulations that prohibit pre-mixed drinks containing caffeine or other stimulants. In the case of pre-mixed alcopops, it might be argued that restrictions are aimed at addressing the risks associated with additives, such as flavorings and mixers. At their core, however, it appears such bans are not applied to address risks arising from additives but are more concerned with the attractiveness of the end product to specific groups. It is less clear whether the same can be said for drinks with caffeine or other stimulants. In the case of the United States, for example, the U.S. Food and Drug Administration (FDA) referred to caffeine as an additive so as to permit invocation of FDA regulatory powers. 19 Notwithstanding the ordinary wording of the definition of SPS measures, in practice WTO Members have tended to raise concerns relating to measures affecting alcoholic beverages through the TBT Committee, suggesting that most Members view the TBT Agreement as being the applicable agreement. 20 This past practice also suggests that restrictions on alcopops, caffeinated beverages and alcoholic energy drinks are likely to be notified to and discussed in the TBT Committee. 21 Despite the limitations on the scope of the TBT Agreement, it is worth noting that WTO case law tends to seek consistent approaches to interpreting rules restricting regulatory autonomy across different WTO covered agreements. 22 Accordingly, the TBT disputes may still be relevant to interpretation of other agreements, including the SPS Agreement. This issue is discussed in Part III.
III. UNITED STATES-CLOVE CIGARETTES AND NON-DISCRIMINATION
UNDER ARTICLE 2.1
In 2009, the United States prohibited cigarettes containing a constituent that is a characterizing flavor of tobacco or tobacco smoke, other than menthol or tobacco. 23 Indonesia brought a WTO complaint, which alleged the law violates Article 2.1 because it treats Indonesian clove flavored cigarettes less favorably than like U.S. menthol flavored cigarettes. 24 Article 2.1 of the TBT Agreement provides that: "Members shall ensure that in respect of technical regulations, products imported from the territory of any Member shall be accorded treatment no less favourable than that accorded to like products of national origin and to like products originating in any other country." 25 Indonesia argued that although the technical regulation did not discriminate against imported products on its face, the effect was nonetheless discriminatory.
26
Indonesia's argument was based on the fact that clove cigarettes consumed in the United States prior to implementation of the law were predominately Indonesian in origin, whereas menthol cigarettes consumed in the United States are predominately of U.S. origin. 27 The United States argued that the regulatory distinction drawn between clove and menthol cigarettes was based not on the foreign origin of clove cigarettes, but on the fact that clove cigarettes are a "starter product" used disproportionately by youth. 28 That is, youth and adults consume menthol cigarettes in similar proportions, whereas clove cigarettes were consumed predominantly by youth. 29 To establish that a technical regulation violates Article 2.1 on national treatment grounds, a complainant must establish that the products in question (clove and menthol cigarettes) are like products and that the imported products (clove cigarettes) are treated less favorably than the products of national origin (menthol cigarettes).
30
Prior to United States-Clove Cigarettes, the approach to be used in determining whether products are like under the TBT Agreement was not clear. The panel examined whether clove and menthol cigarettes were like in regulatory terms. 31 That is, the United States was pursuing the objective of reducing youth smoking and in this light the panel examined whether clove and menthol cigarettes were like in terms of their effect on youth smoking. 32 On the facts, the panel found the products to be like. The panel found that each type of cigarette imparts a characterizing flavor that reduces the harshness of tobacco, and that each is attractive to youth.
33
On appeal, the Appellate Body clarified that whether product categories are to be considered like is "a determination about the nature and extent of a competitive relationship between and among the products at issue." 34 Under this approach, the fact that products may pose divergent risks to health will not in and of itself mean that they are not like products, but may be relevant to the question of competitiveness. 35 Despite interpreting the likeness test differently from the panel, the Appellate Body upheld the panel's finding that clove and menthol cigarettes are like for purposes of this dispute. 36 The Appellate Body also noted that it is sufficient for a sub-group of the population (in this case youth) to treat the products as competitive in order for likeness to be established. On the question of less favorable treatment, the panel sided with Indonesia. 38 On appeal, the Appellate Body sought to clarify the meaning of less favorable treatment. The Appellate Body clarified that mere detriment to some imported products will not satisfy the requirement. 39 The Appellate Body stated, "Article 2.1 should not be interpreted as prohibiting any detrimental impact on competitive opportunities for imports in cases where such detrimental impact on imports stems exclusively from legitimate regulatory distinctions." 40 To determine whether a detrimental impact stems exclusively from legitimate regulatory distinctions, a panel must scrutinize "the design, architecture, revealing structure, operation and application of the technical regulation at issue, and, in particular, whether that technical regulation is even-handed." 41 After elaborating this test, the Appellate Body upheld the panel's finding that less favorable treatment had been established. 42 In doing so, the Appellate Body relied on the fact that the prohibited products were primarily clove cigarettes from Indonesia, whereas the permitted products (menthol cigarettes) were primarily domestically produced. 43 The Appellate Body stated that it was not persuaded that the detrimental impact on competitive opportunities for imported cigarettes stemmed from a legitimate regulatory distinction. 44 Rather, the Appellate Body relied on the panel's findings to the effect that menthol cigarettes had the same product characteristics as clove in terms of their effect on rates of youth smoking. 45 
A. SIGNIFICANCE IN TERMS OF WTO LAW
United States-Clove Cigarettes was the first of three challenges to different U.S. technical regulations. In each of these three disputes, complaints were brought under both Articles 2.1 and 2.2 of the TBT Agreement. 46 Because there had been relatively few disputes touching on these principles of non-discrimination and necessity within the TBT context, United States-Clove Cigarettes marked an important point in development of the law. Prior to United States-Clove Cigarettes, disputes under the General Agreement on Tariffs and Trade (GATT 1994) had served to clarify the balance of rights (to regulate) and obligations. 47 The GATT 1994, which applies to trade in goods, establishes a rule-exception relationship between principles of non-discrimination and necessity. Where a measure is discriminatory in form or effect under Article III, it may nonetheless be lawful if justified in accordance with one of the general exceptions in Article XX, such as the necessity exception in paragraph (b). 48 Consequently, the need to balance the rights and obligations of Members in applying Article III of the GATT 1994 is 38 Id. ¶ 9. 39 limited because Article XX serves as a policy balancing mechanism preserving measures that, inter alia, are necessary to protect human life or health.
Article III:4 of the GATT 1994 prohibits WTO Members from treating imported products less favorably than like domestic products in respect of all laws, regulations, or requirements affecting their internal sale, offering for sale, purchase, transportation, distribution, or use. 49 Under this provision, whether products are like is also determined by reference to the nature and extent of a competitive relationship between them. 50 Whether imported products are treated less favorably also turns on whether the conditions of competition are modified to the detriment of imported products. 51 A panel, however, is not required to ask whether the detriment to imported products is based solely on a legitimate regulatory distinction. Rather, a panel must look more generally at the explanations for the detrimental effect. 52 As the Appellate Body has stated, "the existence of a detrimental effect on a given imported product resulting from a measure does not necessarily imply that this measure accords less favorable treatment to imports if the detrimental effect is explained by factors or circumstances unrelated to the foreign origin of the product." 53 In the event that a measure violates Article III:4, the measure may nonetheless be justified under Article XX(b) on grounds that it is necessary to protect human life or health. 54 This exception is subject to a requirement set out in the chapeau that the measure not be "applied in a manner which would constitute a means of arbitrary or unjustifiable discrimination between countries where the same conditions prevail, or a disguised restriction on international trade." 55 This passage governs only how a measure is applied and not the form of a measure itself. When considering questions of application, the test is whether reasons given for discrimination in application of the measure bear a rational connection to the objective or go against that objective.
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Because Article 2.1 of the TBT Agreement is not subject to general exceptions along the lines of those in Article XX, it was foreseeable that United States-Clove Cigarettes would alter the balance of rights and obligations reflected in the GATT 1994. To avoid this, the panel took a distinct approach to likeness by following the approach to interpretation used in investment treaties, which usually lack general exceptions along the lines of GATT Article XX. 57 The effect of this was to narrow the scope of the non-discrimination obligation relative to that in the GATT 1994. In rejecting the panel's approach, the Appellate Body stated that under its approach the balance between rights and obligations in Article 2.1 of the TBT Agreement "is not, in principle, different from the balance set out in the GATT 1994 59 the extent to which Members must do this under the GATT 1994 is less clear. One line of case law suggests the legitimacy of a regulatory distinction between products is only evaluated under the chapeau of Article XX. For example, the Appellate Body's decision in United States-Gasoline held that a Member must establish the necessity of a measure as a whole and not the necessity of discrimination under Article XX(b). 60 Under this approach, a Member would not have to establish the legitimacy of a regulatory distinction between products in order to establish necessity (although the discrimination may be weighed and balanced in the analysis). 61 Moreover, the chapeau only governs application of a measure and not the form of the measure itself (such as where an otherwise neutral measure is applied in a discriminatory manner).
62 As a result, there is a very narrow range of circumstances in which a Member will have to justify regulatory distinctions between measures.
However, in a more recent dispute and without expressly referring to the earlier authority, the Appellate Body stated that where violation of Article III occurs, it is the discrimination that must be justified as necessary and not the measure. 63 The decision in Thailand-Customs and Fiscal Measures on Cigarettes from the Philippines suggests a respondent will have to justify a discriminatory regulatory distinction drawn between like products in order to establish the necessity of the measure. 64 In short, if this more recent approach to the GATT 1994 prevails, the Appellate Body's observation in United States-Clove Cigarettes that the balance between rights and obligations are similar under the GATT and TBT Agreement would appear to be correct. However, if the earlier approach prevails, the GATT 1994 might be more permissive than Article 2.1 of the TBT Agreement.
To add to the confusion, since United States-Clove Cigarettes, the Appellate Body has equated the concept of a legitimate regulatory distinction with compliance with the chapeau of GATT Article XX. In United States-COOL, the Appellate Body stated that a distinction would not be legitimate if it "is designed or applied in a manner that constitutes a means of arbitrary or unjustifiable discrimination." 65 The notable distinction here is that this passage refers to regulations "designed or applied" whereas the chapeau only governs application of a measure.
B. APPLYING THE TEST TO MEASURES ADDRESSING NCDS
Leaving aside resolution of the prevailing approach, it is clear that demonstrating the legitimacy of regulatory distinctions will sometimes be challenging for regulators in the contexts of tobacco, alcohol, and diet. The legitimacy of a distinction must ultimately be based on an analysis of the risks posed by the relevant product categories. Unlike the SPS Agreement, however, the TBT Agreement offers no guidance on the issue of what type of risk assessment or evidence is adequate. 67 This poses a particular challenge in the context of NCDs like cancers, diabetes, or stroke because many risk factors are distal from, rather than proximate to, the onset of disease. These risk factors are often related to complex patterns of consumer behavior, such as an unhealthy diet over long periods.
Before considering the evidence used to justify regulatory distinctions in this context, it is worth noting that the burden of proof rests with the complainant to show that imported products are treated less favorably than like domestic products.
68
If the complainant adduces evidence and arguments to show that the measure is not even-handed, the burden then shifts to the respondent to show that the detrimental impact on imported products stems exclusively from a legitimate regulatory distinction.
69
Regulations drawing distinctions between products for purposes of addressing NCDs tend to be based on two types of evidence. First, a regulation may be based on evidence of the health risks associated with consumption of a particular product, for example, the risks associated with using an electronic cigarette. For distal causes of disease, this evidence is often collected through longitudinal cohort studies carried out over long periods of time. 70 While controlling for other factors, these studies compare the disease burden of different groups (cohorts) in order to evaluate the disease burden associated with particular products or product constituents, i.e., whether there was a positive association between consumption of electronic cigarettes and the onset of disease. 71 Second, a regulation may be based on evidence of consumer behavior causing heightened risk. For example, in United States-Clove Cigarettes, the United States argued that clove cigarettes pose a greater health risk than menthol cigarettes due to the former being particularly attractive to young people. 72 The panel failed to engage with the evidence on this issue by stating that each disputant presented conflicting evidence using different methodologies that did not permit a finding of fact.
73
Although the Appellate Body criticized this aspect of the decision, 74 the dispute does highlight how difficult it can be to provide compelling evidence of risk based on consumer behavior or preferences. In this respect, the Appellate Body went to lengths to explain a panel's obligation: 67 See TBT Agreement, supra note 10. 68 
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We acknowledge that extracting meaningful information from surveys that differ considerably in terms of research parameters might not be an easy task. Likewise, we do not suggest that panels must always be capable of engaging in sophisticated statistical exercises to solve data discrepancies that ultimately cannot be resolved. However, the fact that evidence relied on by the parties may be difficult to compare cannot excuse the panel from examining it. A panel has the obligation to "consider all the evidence presented to it," and it should at least attempt to extract potentially relevant information contained therein. It is only after such an examination that a panel might be able to provide "reasoned and adequate explanations" as to why it cannot or chooses not to rely on specific evidence submitted by the parties. In our view, a panel cannot determine a priori that some pieces of evidence are not reliable for the purposes of its analysis solely on the basis of a difference in the parameters and methodology used.
75
Leaving evidentiary difficulties concerning legitimacy to one side, there is an evidentiary question of how a respondent can show that detriment to imports is based solely on that regulatory distinction and not on other factors. The first question to consider here is what it means for detriment to be "based on" a regulatory distinction. Case law interpreting this phrase in the context of Article 5.1 of the SPS Agreement suggests that the regulation must be rationally related to the regulatory distinction. 76 In United States-Tuna II, however, the Appellate Body appeared to set the bar higher by examining whether the U.S. measure at issue was "calibrated" to the risks the United States was seeking to address. 77 By adopting this approach the Appellate Body appears to be using a proportionality standard. This view is reinforced by discussion in United States-COOL, where the Appellate Body concluded that the informational requirements imposed on meat producers were disproportionate to the level of information actually passed on to consumers. 78 It is worth noting that a proportionality test would be more difficult for a respondent to satisfy than a rational relationship test.
It is also worth noting that whether a distinction is legitimate is a separate question to whether the regulation is based on that distinction. The former was at issue in United States-Clove Cigarettes. 79 Although there was no standard articulated in that dispute against which the legitimacy of a regulation should be judged, 80 United States-COOL suggests that the issue may turn on a GATT Article XX chapeau standard.
The second question to consider is how a respondent could establish that a measure is based solely on a legitimate regulatory distinction. The Appellate Body has not given any guidance on how this term will be interpreted where a regulatory distinction is legitimate. In this respect, a number of commentators have argued that this fails to take account of "messy regulation," where regulators and legislators adopt policies beneficial to the public interest but with mixed motives. The practical significance of these issues in a regulatory context can be further illustrated by deeper exploration of specific examples in the contexts of tobacco, alcohol, and diet.
C. TOBACCO CONTROL
In the context of tobacco control, regulatory distinctions appear in a number of forms. For example, tobacco taxes sometimes apply different tax rates to different product categories. 82 Similarly, packaging and labeling measures are often tailored to specific products or may include exemptions, such as for cigars sold as single sticks. 83 Most importantly, regulatory distinctions are drawn by product regulations including product bans and restrictions on additives and characterizing flavors. Regulatory distinctions and also drawn by regimes that treat tobacco products and cessation aids differently. An example of an outright product ban can be observed in the EU, where snus is prohibited (with the exception of in Sweden) but other tobacco products are permitted. 84 United States-Clove Cigarettes provides an example of a restriction on additives and flavors, as does a Brazilian regulation discussed below. 85 Tobacco product regulation occurs against a backdrop of controversy within the public health and scientific community concerning harm reduction. A number of emerging tobacco and nicotine products, such as electronic cigarettes, nicotine handcreams and gels, and nicotine infused drinks and foods, have generated controversy. On the one hand, some argue that these products, like flavored cigarettes, are starter products that are particularly attractive to young people. 86 As the argument goes, in addition to the risks inherent in consuming these products there is a population health risk that these products will facilitate nicotine addiction and ultimately lead to increased tobacco consumption, morbidity and mortality. 87 On the other hand, it has also been argued that these products are likely to be less harmful to health than cigarettes because some other non-combustible products, such as snus, have a disease burden distinct from cigarettes. 88 In many countries, these emerging products fall within legislative or regulatory gaps. Many of the products fall outside the scope of tobacco control laws and regulations, as well as outside laws and regulations governing the marketing and sale of tobacco cessation aids. Expert advisory groups have advised taking a precautionary approach to products such as electronic cigarettes on the basis that long-term observational studies, such as longitudinal cohort studies, are required in order to assess risk, but cannot be conducted without permitting sale of the products. 89 It is implicit in this approach that some products may be prohibited outright for failure to gain regulatory approval as cessation aids. Given the state of the science on many emerging products, and the inherent limitations of scientific methods, drawing legitimate regulatory distinctions may be particularly difficult in this context if the evidentiary standard is set high.
For reasons relating to political economy, however, controversy has focused more on established products. For example, Brazil has introduced a regulation banning the use of additives other than sugar in the production of tobacco products.
90
A number of WTO Members have objected to the measure in the TBT Committee, arguing that the effect of the measure is to ban blended tobacco products that use additives to mask the harsh flavor of burley. 91 These Members argue that the effect of the measure is to discriminate against imported products because the Brazilian tobacco market is comprised primarily of cigarettes containing flue-cured tobacco rather than blended tobacco.
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How would the like products test apply to this example? The fact that likeness under Article 2.1 is about the nature and extent of a competitive relationship between products is significant. This, along with prior case law, suggests that different categories of tobacco products will ordinarily be considered like products for purposes of Article 2.1, irrespective of the relative risks to health posed by those products. Moreover, even if there is clear market segmentation between product categories, this will not preclude a finding of likeness if one segment of the population treats the products as interchangeable.
93
How would the less favorable treatment standard apply to this example? As discussed above, the application of this standard turns first on the effects of a measure on the competitive opportunities of imported products. 94 If it is assumed for the sake of argument that the majority of cigarettes with additives consumed in Brazil were of foreign origin, United States-Clove Cigarettes suggests that the burden would rest with Brazil to show that the effect on competitive opportunities for imported products is based solely on a legitimate regulatory distinction.
If the objective were to address the improved palatability of products containing additives, the first issue would be whether the regulation is proportional to that objective. In this respect, there appears to be quite a close relationship between the ban on additives and such an objective. The second question would be whether there is a legitimate regulatory distinction between products that do and do not contain additives. If a chapeau "rational relationship" standard were applied, there would be a fairly strong argument that the products are distinct based upon their palatability. However, if a higher standard were applied the issue might turn on evidence of consumer perceptions relating to palatability. In such a context, Brazil might need to produce qualitative evidence concerning the palatability of different products. This evidence would be most persuasive if collected in the Brazilian market itself. If this type of evidence were required, it would be implicit that Brazil ought to have based 89 its measure on a reasonably sophisticated assessment of the risks associated with different product categories. Like the requirement to base an SPS measure on a risk assessment under Article 5.1 of the SPS Agreement, a similar evidentiary requirement in the TBT Agreement could prove to be a barrier to regulation. More specifically, if the evidentiary requirement is interpreted too strictly, there is a risk that rational regulation of emerging products will not be permissible until after the predictable risks associated with those products have manifested and been studied. This would marginalize the role of precaution in policymaking in a context where the apparent risks are not merely theoretical but logically flow from the known risks associated with existing products with similar characteristics.
On the other hand, the limited analysis of the facts conducted at first instance by the panel in United States-Clove Cigarettes meant that the Appellate Body was left to draw comparisons between the objective features of clove and menthol cigarettes rather than to rely on a detailed factual record concerning consumption patterns. In this context, it might be argued that theoretical arguments about product characteristics will be sufficient. However, it remains to be seen how this will play out in future disputes.
D. ALCOHOL CONTROL
WTO Members draw regulatory distinctions between product categories of alcoholic beverages in a number of contexts. The most common regulatory distinction is found in graduated or differential tax schemes, which usually tax products with higher alcohol per volume at a higher rate than products with lower alcohol per volume. 95 The underlying goals of this approach are to reduce total consumption of alcohol at the population level and to reduce excessive consumption in a single sitting. 96 These goals may also be pursued through other measures, such as restrictions on the sale of certain products in particular types of stores.
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Other common forms of regulation include the banning of certain product constituents or categories. For example, many WTO Members prohibit the presence of methanol, a known toxin, in alcoholic beverages. 98 More controversially, over recent years a number of WTO Members (or political sub-divisions thereof) have prohibited, or considered prohibiting, specific product categories such as "alcopops," 99 caffeinated alcoholic beverages, and alcoholic beverages pre-mixed with stimulants, such as energy drinks.
For example, in June 2012, New Zealand notified the WTO that a new policy aimed to reduce "ready-to-drink" products could affect trade in products with an alcohol content of between six to fourteen percent. 100 The proposed regulations 95 See LAW COMM'N, ALCOHOL IN OUR LIVES: CURBING THE HARM 289 (2010), available at http://www.lawcom.govt.nz/project/review-regulatory-framework-sale-and-supply-liquor/publication/ report/2010/alcohol-our-lives. 96 Id. 
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would prohibit the sale of higher-alcohol content products in liquor stores, making them only available in restaurants and bars. 101 The treatment of different products would be based on their alcohol content and the number of standard drinks contained in a serving. 102 These prohibitions have been justified on the grounds that alcopops are particularly appealing to young people, may serve as a "starter product" and are used heavily in binge drinking. 103 Similarly, the FDA took enforcement action concerning pre-mixed drinks containing caffeine, arguing that caffeine is an unsafe food additive. 104 The enforcement action came after estimates that the beverages were consumed regularly by thirty-one percent of twelve to seventeen year-olds and thirty-four percent of eighteen to twenty-four year-olds. 105 There are also studies showing higher rates of binge drinking and sexual assault in contexts where these drinks are consumed. 106 As the discussion in Part II suggests, restrictions on retail sale of the type contemplated by New Zealand are unlikely to be considered technical regulations. 107 On the other hand, outright prohibitions on the sale of particular product categories such as alcopops would be technical regulations. With this in mind, an outright prohibition on alcopops is worth examining as a case study. A WTO Member challenging the regulation might argue that it treats imported alcopops less favorably than other beverages produced domestically. These beverages might include spirits that are not premixed, or other beverages such as beer or wine. On the question of likeness, the relatively low threshold discussed above suggests that alcopops could be considered like any of the other products listed. 108 As such, the analysis would turn first to the question of how the conditions of competition between domestic and imported products are affected. In an extreme hypothetical, it might be the case that all alcopops are imported and the WTO Member in question otherwise has a strong domestic alcoholic beverage industry. For example, the Member might be a major wine producing country, as New Zealand is. In such a situation, there would be no doubt that the measure affects the competitive opportunities of importers negatively, meaning that lawfulness would turn on whether the regulation is based solely on a legitimate regulatory distinction.
The regulatory concern with respect to alcopops is the effect these products have on consumption patterns. In this instance, concerns relate to the appeal of the products to young people due to the flavor, the similarity with soft drinks, and the ease with which alcopops can be consumed. 109 The legitimacy of the regulatory distinction between alcopops and wine would thus turn on the strength of the evidence that alcopops are particularly attractive to a specific group of consumers. Additionally, a respondent would have to show that this particular attractiveness results in some additional negative health outcome, such as increased binge drinking or increased drinking by that group (as opposed to pure substitution of one product for another). The question of greater concern in this example is how a Member would show that the regulation is based solely on this distinction. Although the regulation may be proportional to the objective, other factors could suggest a protectionist purpose and it remains to be seen how such a hypothetical would be resolved in practice.
E. DIET
In the context of diet, regulatory distinctions are drawn in a wide array of situations. Most often, distinctions are drawn between products based upon the threat to health posed by additives, contaminants, toxins or disease-causing organisms. 110 This involves placing maximum limits on certain ingredients in foods or beverages and sometimes prohibiting those ingredients, or entire classes of foods or beverages, outright. 111 In the specific context of obesity prevention, regulatory distinctions are drawn to promote a balanced diet. These distinctions include differential or graduated taxation based, for example, on the fat content of products, 112 soda taxes, restrictions on the sale of soda in packages above a certain size, 113 and outright product bans such as for high fat cuts of meat like turkey tails and mutton flaps. 114 As was discussed above, these measures will ordinarily fall within the scope of the SPS Agreement. 115 Article 5.5 of that agreement is the provision most relevant to the drawing of regulatory distinctions, and obliges each WTO Member to avoid arbitrary or unjustifiable distinctions in the levels of protection it considers to be appropriate for different situations, if such distinctions result in discrimination or a disguised restriction on international trade. 116 The application of this provision to obesity prevention measures has been discussed elsewhere. 117 The important thing to note here is the parallel between the approach to determining when a regulatory distinction is legitimate and application of Article 5.5. As United States-COOL illustrates, a panel might use a similar test to determine whether a distinction is legitimate. Accordingly, many of the same issues considered above in the context of tobacco and alcohol may be relevant in the food context. One difference, however, is that the SPS Agreement contains more specific rules governing risk assessment and the circumstances in which a precautionary approach to policymaking is permissible. The analysis above is not intended to suggest that regulations aimed at risk factors for NCDs will violate Article 2.1 of the TBT Agreement. Rather, the overarching point is that the test set out in United States-Clove Cigarettes tinkers with the balance of rights and obligations under WTO law. In doing so, the test raises questions about the evidentiary burden on WTO Members implementing health regulations. These questions appear most relevant in the context of measures to address NCDs, due to the nature of the evidence on which such measures are based. In this context, WTO panels and the Appellate Body need to be aware of the limitations of scientific evidence, and the methods used in this field of policymaking as the test develops incrementally through settlement of future disputes. 126 Three primary reasons were given for rejecting Indonesia's claims. First, Indonesia argued that the ban exceeded the level of protection sought by the U.S. (i.e., that it was disproportionate to the regulatory goal). 127 The panel, however, held that Indonesia had not provided sufficient evidence to establish the level of health protection pursued by the United States. 128 Hence, Indonesia could not establish that the ban exceeded that level of protection. 129 Second, Indonesia argued the ban on clove flavored cigarettes made no material contribution to the objective of reducing youth smoking. 130 The panel rejected this argument, stating that "this is a case in which the measure actually represents at least the majority view, and potentially the unanimous view." 131 The Panel noted its understanding on the issue was reinforced by WHO FCTC Partial Guidelines on Articles 9 and 10-Regulation of the Contents of Tobacco Products and Regulation of Tobacco Product Disclosures.
132 These Guidelines are one in a series developed by consultative processes and adopted by the FCTC's Conference of the Parties (COP) with the aim of assisting Parties to meet their obligations under the convention. 133 The panel stated that the Partial Guidelines "show a growing consensus within the international community to strengthen tobacco-control policies through regulation of the content of tobacco products, including additives that increase the attractiveness and palatability of cigarettes." 134 The potential significance of the Partial Guidelines for future disputes will be discussed further below. 135 Finally, Indonesia argued there were less trade restrictive alternative measures to the ban that were reasonably available to the United States. 136 The panel concluded Indonesia had simply listed a number of tobacco control measures relating to reducing youth smoking as alternatives, each of which involved a greater risk of non-fulfillment of the objective compared with the outright ban at issue. 137 As such, it was difficult to see how the measures could make an "equivalent" contribution to achievement of the objective, at the level of protection sought by the United States. 138 Even if Indonesia's listing of alternative measures was sufficient to establish a prima facie case, the Panel felt the United States had rebutted this by showing that many of the alternative measures proposed were already in place, suggesting these were complementary measures rather than true alternatives.
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Although the panel report illustrates how Article 2.2 applies to a particular tobacco control regulation, the absence of an appeal by Indonesia suggests the decision may not be of great systemic importance. As mentioned in relation to Article 2.1, United States-Clove Cigarettes was the first of three challenges to different U.S. technical regulations decided in 2012. 140 For the first time, these disputes specifically analyzed issues of discrimination and necessity as they operate in relation to technical regulations.
Prior to this, context had been provided by similar language in the GATT 1994 in relation to general restrictions on trade in goods. 141 In the case of Article 2.2, parallels can be drawn with the GATT Article XX(b) exception, allowing certain otherwise discriminatory measures to remain lawful where these are, inter alia, necessary to protect human health.
Without attempting to give a comprehensive summary of the significant jurisprudence developed under Article XX(b), some broad observations about the components of a necessity analysis conducted under that exception can be made. Analysis under Article XX(b) proceeds in four stages, the first of which involves determination of whether the measure violating the GATT could be described as a measure for the protection of human life or health. 142 In a second stage, a panel weighs and balances a range of factors in order to make a preliminary determination of whether the measure is necessary to achieve the Member's regulatory goal. 143 Relevant considerations include the contribution of the measure to achievement of the goal and the measure's trade restrictiveness. 144 These factors are weighed in light of the importance of a Member's regulatory goal. 145 If a measure survives this preliminary determination of necessity, the third step may involve analysis to determine whether less trade restrictive, reasonably available alternative measures exist. 146 Lastly, a panel will examine compliance with the chapeau of Article XX, to check the measure is not "applied in a manner which would constitute a means of arbitrary or unjustifiable discrimination . . . or a disguised restriction on trade."
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As it will be seen, similar considerations may be used by panels in a TBT context. This notwithstanding, important differences in structure, scope, and the relationship between Articles 2.1 and 2.2 compared to their GATT counterparts command consideration of their practical operation. In particular, the status of Article 2.2 as a freestanding obligation, and differences in relevant burden of proof may have important implications for legal analysis, and ultimately the outcome of any challenge to a given regulation.
Since United States-Clove Cigarettes, the Appellate Body has considered Article 2.2 in United States-Tuna II and United States-COOL. 148 In United
States-Tuna II, the Appellate Body largely confirmed the approach of the panel to Article 2.2, stating: A panel should begin by considering factors that include: (i) the degree of contribution made by the measure to the legitimate objective at issue; (ii) the trade restrictiveness of the measure; and (iii) the nature of the risks at issue and the gravity of consequences that would arise from non-fulfilment of the objective(s) pursued by the Member through the measure. 149 The Appellate Body has also clarified that in determining the contribution of a regulation, it is not that the regulation "must meet some minimum threshold of fulfilment." 150 Rather, "a panel must seek to ascertain to what degree, if at all, the challenged technical regulation, as written and applied, actually contributes to the legitimate objective pursued by the Member." 151 To this end, assessment will be made as to whether the regulation at issue is capable of achieving the legitimate objective. 152 The Appellate Body added, "The degree of achievement of a particular objective may be discerned from the design, structure, and operation of the technical regulation, as well as from evidence relating to the application of the measure," such that "a panel must assess the contribution to the legitimate objective actually achieved by the measure at issue." 153 If a contribution does exist, the trade restrictiveness of the regulation will then be assessed. 154 Where a complainant makes out a prima facie case that a reasonably available alternative regulation exists, the burden will shift to the respondent to show this is not the case. 155 It will be relevant to consider whether the proposed alternative is less trade restrictive; whether it would make an equivalent contribution to the legitimate objective, taking account of the risks non-fulfillment would create; and whether it is reasonably available. 156 The relationship between Articles 2.1 and 2.2 of the TBT Agreement is one issue that remains to be clarified. It might be expected that a discriminatory measure in violation of Article 2.1 would be more trade restrictive than necessary under Article 2.2. That is, the discrimination could not be considered necessary unless based on a legitimate regulatory distinction. Of course, this assumes that discrimination can be equated with the concept of trade restrictiveness, which may not be the case. In United States-Clove Cigarettes, the regulation was ultimately held to violate Article 2.1, but not Article 2.2. 157 This stemmed from the fact that the panel examined not whether the discrimination was necessary, but whether the ban on clove cigarettes was necessary. 158 In United States-Tuna II, the Appellate Body reversed the panel by finding a violation of Article 2.1, but then found no violation of Article 2.2. 159 Although the decision on Article 2.2 was due largely to failings in the panel's earlier approach, 160 the decision could be taken to suggest that it is the 284 AMERICAN JOURNAL OF LAW & MEDICINE VOL. 39 NO. 2&3 2013 necessity of the technical regulation as a whole that must be examined under Article 2.2.
To some extent, this may seem inconsistent with the Appellate Body's more recent approach under the GATT of examining the necessity of discrimination rather than the necessity of a measure. 161 However, that approach is understandable in the context of the GATT where Article XX functions as an exception used for purposes of justifying a violation (such as discrimination). Because Article 2.2 is a freestanding obligation, a narrow approach to trade restrictiveness may apply whereby the test focuses not on the necessity of discrimination, but on whether the impact of a regulation on market access is more trade restrictive than necessary.
Taken as a whole, these decisions suggest that greater deference may be granted to a WTO Member to pursue product regulation under Article 2.2 than 2.1. In fact, it appears that there has been some migration of policy-balancing mechanisms into Article 2.1 due to the absence of an exception to that provision.
As with Article 2.1, a deeper understanding of how this approach to Article 2.2 may affect future regulation can be gained from further examples within the specific tobacco, alcohol, and diet contexts.
B. TOBACCO CONTROL
In the context of tobacco control particularly, the decision in United StatesClove Cigarettes highlights the difficulty of a challenging member in establishing that different types of tobacco control regulations are truly less trade restrictive alternatives. In an era where comprehensive programming practices are now widely accepted as the "gold standard" in tobacco control, WTO Members are likely to have little difficulty in arguing that different types of measures are complementary or cumulative components that operate synergistically to reduce tobacco-related harm, rather than those easily substituted for reasonably available, less trade restrictive alternatives. 162 Also noteworthy in the United States-Clove Cigarettes decision was the Panel's treatment of the FCTC Guidelines. Although neither disputant explicitly asked the panel to consider whether the Guidelines (or specifically, the Partial Guidelines to Articles 9 and 10 in that case) constituted international standards per se, repeated references within the panel report allude to the potential utility of such documents in determining the lawfulness of tobacco product regulations in future TBT disputes. 163 Under the TBT Agreement, WTO Members are obliged to use relevant international standards as the basis for technical regulations except where these would be ineffective or inappropriate to achieve an objective in the circumstances, for example, because of fundamental technological problems. 164 In fact, Article 2.5 of the Agreement creates a presumption that health measures in accordance with relevant international standards do not create unnecessary obstacles to international trade for the purposes of Article 2.2. or characteristics for products or related processes and production methods, with which compliance is not mandatory." 166 The phrase "international standard" is not defined in the TBT Agreement.
167 Accordingly, the phrase is to be interpreted in accordance with ISO/IEC Guide 2 as a "standard that is adopted by an international standardizing/standards organization and made available to the public." 168 In the current absence of a specific determination on the status of the FCTC Guidelines, the recent Appellate Body Report in United States-Tuna II elucidates several relevant criteria. For a particular rule to qualify as an international standard under the TBT Agreement, it must, inter alia, be adopted by a body that (i) has recognized activities in standardization and (ii) is open (in terms of membership) to the relevant bodies of at least all WTO Members. 169 Within the context of tobacco control, the requirement of "voluntariness" of standards suggests that mandatory provisions of the FCTC fall outside the definition of international standards. However, non-mandatory guidelines do appear to meet the definition. 170 Even if the Conference of the Parties to the WHO FCTC does not have recognized activities in standardization, which it may, the WHO does.
171 If recognized as international standards, technical regulations in accordance with the guidelines would benefit from a presumption of lawfulness, or necessity, under Article 2.2.
It is not entirely clear how closely a regulation must be related to an international standard in order to meet the presumption of lawfulness (a measure which clearly contradicts a standard, for example, may be easy to rule out, but "in accordance with" may be harder to define). Nor is it entirely clear how specific an instrument must be in order to constitute an international standard. This notwithstanding, the FCTC Partial Guidelines to Articles 9 and 10 are likely to provide comfort to WTO Members, including Brazil in relation to the proposed additives ban already discussed above. 172 Similarly, in the case of Australia's plain packaging of tobacco products, relevant FCTC Guidelines to Article 11 and 13 could be expected to play a greater role in supporting Australia's regulation under any challenge under Article 2.2. 173 Ultimately, resolution of the Guidelines' status and relevance cannot be made until a direct analysis and determination are made by the Appellate Body. Until then, 166 Id. at Annex 1. 167 the decision in United States-Tuna II seems to confirm how broad the definition of international standards is within the TBT regime.
Recognition of the FCTC Guidelines as international standards would be favorable for domestic regulatory autonomy, providing WTO Members with space to enact tobacco control regulations that offer a high level of health protection. Within a WTO regime where concern has been raised about industry-influenced or privately created standards, such recognition may also be seen by the public health community as endorsement of global health priorities and integration of the international trade and health regimes.
C. ALCOHOL CONTROL
As the NCD agenda gains heightened global awareness, states are increasingly using lessons learned in tobacco control to address other common risk factors for these conditions, including harmful alcohol use.
In an area where there exists no binding FCTC equivalent, Thailand's proposed graphic warning labels on alcohol provide a good example of potential challenges within WTO law. In 2010, as part of a package of alcohol reform, Thailand proposed implementation of graphic warnings on both imported and locally produced alcohol in an attempt to tackle rapidly rising harm associated with increased alcohol consumption. 174 Specifically, Thailand's proposed regulation involves colored graphic labels accompanied by warning statements to be rotated at 1000-package intervals, similar in form to those gaining international favor in the tobacco context, in which Thailand was also an early adopter. 175 The suggested content of these warnings is varied: from matters commonly accepted in annals of international medicine, i.e., "Drinking alcohol causes hypertension liver cirrhosis," to broader and potentially more categorical claims, i.e., "Drinking alcohol leads to unconsciousness and even death." 176 As a regulation likely to affect trade, and one arguably not based on any relevant international standard, Thailand provided notice to other WTO Members of its intention under Article 2.9 of the TBT Agreement. 177 As of January 2013, despite international discussion in several rounds of TBT Committee meetings, it appears Thailand has made little progress in implementation of the regulation. 178 WTO members' concerns with the proposed regulation relate principally to Article 2.2. A primary concern is the legitimacy of Thailand's regulatory objective. Comments of WTO Members, including the EU, Chile, and Mexico, challenge the legitimacy of the warnings on the basis that they suggest any level of drinking could lead to health problems. 179 These Members argue that it is not drinking per se, but excessive drinking that is the problem, implying that regulation should properly be directed only at harmful alcohol use. 180 Thailand has so far suggested several objectives of the proposed regulation, including not only prevention of alcoholrelated harm, but also prevention of alcohol consumption broadly, as well as provision of information to consumers about risk. 181 Unlike members with historically high but stable patterns of consumption such as the EU, Thailand argues there is no such thing as "risk-free drinking" within its domestic context. 182 Compared with limited evidence of cardiovascular benefit in France, for example, Thailand refers to a lack of beneficial association with any level of consumption in low-and middle-income countries. 183 It also points to the Thai population's recent and rapidly increasing patterns of use, particularly high disease burden, and the role of marketing and packaging as a critical vector for the epidemic within its borders. 184 Characterization of Thailand's regulatory objective would then shape analysis of whether the regulation is more trade restrictive than necessary under Article 2.2. It is the contribution of the regulation to the objective that must be assessed. Several Members have questioned the scientific basis of both the form and content of the proposed labels. 185 In this respect, evidence would need to be brought of the contribution of graphic warning labels to the regulatory objective. This contribution would be weighed against trade restrictiveness, which arguably should not be concerned with the content of the health message involved, but only the imposition of requirements different or more onerous to other countries that may therefore create a barrier to market access. By this view, TBT analysis by a panel would ask whether warnings are more trade restrictive than necessary to protect health, but would not be concerned with the content of the warnings themselves.
Consideration may also be given to the availability of less trade restrictive reasonably available alternatives. Some Members have so far listed alternatives such as education and information campaigns. 186 However, Thailand already implements many of these, suggesting they may be complementary or cumulative regulations, rather than reasonably available alternatives. 187 There would also be a question as to whether such measures would achieve Thailand's objective.
Accepting that other factors such as domestic politics or budgets may also be at play, Thailand's apparent stall in legislative developments despite the evident health burdens associated with alcohol, highlights the potential of WTO proceedings (real or threatened) in creating regulatory chill. Interestingly, several of the WTO Members expressing objection to Thailand's proposal, including Australia, already employ similar graphic warning labels on tobacco. 188 Several objecting Members also have prominent alcohol industries. 189 While not necessarily of direct relevance to any potential legal analysis, such factors highlight the reality of complex and potentially competing interests of WTO Members in both exercising their own domestic regulatory autonomy, and respecting that of others. In the absence of an equivalent legal framework to the WHO FCTC and its Guidelines in the alcohol context, it appears unlikely that countries such as Thailand would be able to support the lawfulness of regulation based on international standards. Although the World Health Assembly endorsed the adoption of a nonbinding Global Strategy to Reduce the Harmful Use of Alcohol (Global Strategy) in 2010, 190 it is unclear whether such a document would constitute an international standard gaining the benefit of an Article 2.5 presumption. Although explicitly intended to give guidance for global action and recognizing the right of countries to make health regulations that may have trade implications, 191 it is open to question whether the broad portfolio of policies contained by the Global Strategy are sufficiently specific to act as standards capable of common and repeated use.
Assuming the current absence of relevant international standards, the decisions in United States-Clove Cigarettes and United States-Tuna II may still provide guidance for future development of international instruments in an alcohol context. Those interested in ensuring a degree of regulatory autonomy for states to take public health measures more likely to withstand WTO scrutiny may prefer such instruments are developed with attention to the definition of international standards offered in United States-Tuna II, and any future decisions concerning the status of WHO FCTC guidelines.
D. DIET
As was mentioned above in the discussion of Article 2.1, the TBT Agreement does not apply to most regulations addressing diet because the SPS Agreement takes precedence. 192 Although the SPS Agreement includes a necessity requirement similar to that found in Article 2.2 of the TBT Agreement, 193 the implications of United States-Clove Cigarettes for interpretation of that provision appear to be minimal. There is a well-established body of case law on the SPS Agreement, and disputes tend to focus on compliance with the obligations in Article 5, rather than on the general obligations concerning necessity. 194 
V. CONCLUSION
United States-Clove Cigarettes was the first in a series of three intriguing TBT disputes. Because the Appellate Body had not clarified application of the TBT Agreement before these disputes were afoot, each of the panels approached the issues differently from the way subsequently preferred by the Appellate Body. This left holes in the factual records that forced the Appellate Body to work with the information available. This was most evident in United States-Clove Cigarettes, where the Appellate Body ruled that there was no legitimate regulatory distinction
